Status:

TERMINATED

Trial of Antibody Responses by Vitamin Supplementation

Lead Sponsor:

St. Jude Children's Research Hospital

Collaborating Sponsors:

The Gerber Foundation

Conditions:

Healthy Participants

Eligibility:

All Genders

1-4 years

Phase:

PHASE1

Brief Summary

Streptococcus pneumoniae, commonly called pneumococcus, can cause a wide range of diseases in children from mild ear infections to deadly pneumonia or meningitis. Vaccination is currently the single b...

Detailed Description

Children between the ages of 1 and 4 years old (inclusive) will be enrolled. All will receive PCV and hepatitis A vaccination. Those randomized to the treatment arm will receive 10,000 IU orally at th...

Eligibility Criteria

Inclusion

  • Between 1 and 4 years old (inclusive) at the time of enrollment
  • Fully weaned from breast-feeding or formula-feeding for at least 4 weeks prior to vaccination date (Day 0).
  • Received at least 2 doses of Prevnar-13 vaccination
  • Parent or legal guardian willing and able to provide informed consent.

Exclusion

  • Current use of investigational or immunosuppressive drugs (e.g., steroids) at the time of enrollment
  • Parent/guardian planning to continue (or initiate) the administration of daily vitamin A, vitamin D, or multivitamin to the child during the study period.
  • Evidence of developmental delay or evolving neurological disorders at screening.
  • Current use of antibiotics or antivirals at enrollment.
  • Currently receiving cancer related treatment.
  • History of heart, kidney, or chronic respiratory condition (e.g., asthma) conditions.
  • History of diabetes.
  • Acute febrile illness \[e.g., \>100.0F (37.8oC) oral\] illness within 3 days prior to enrollment.
  • Received a previous PCV13 vaccine within 2 months of the enrollment date (Day 0).
  • Received hepatitis A vaccine previously.
  • Ever had a life-threatening allergic reaction to a dose of PCV13 vaccine, to an earlier pneumococcal vaccine called PCV7, or to any vaccine containing diptheria toxoid (for example, DTaP).

Key Trial Info

Start Date :

August 19 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 10 2025

Estimated Enrollment :

22 Patients enrolled

Trial Details

Trial ID

NCT03859687

Start Date

August 19 2019

End Date

July 10 2025

Last Update

September 5 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

St. Jude Children's Research Hospital

Memphis, Tennessee, United States, 38105

Trial of Antibody Responses by Vitamin Supplementation | DecenTrialz